Rifampin - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for rifampin and what is the scope of freedom to operate?
Rifampin
is the generic ingredient in three branded drugs marketed by Sanofi Aventis Us, Chartwell Molecular, Epic Pharma Llc, Hikma, Lupin Pharms, Oxford Pharms, Avet Lifesciences, Fresenius Kabi Usa, Hikma Pharms, Mylan Labs Ltd, and Watson Pharms Teva, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.There are nine drug master file entries for rifampin. Fifteen suppliers are listed for this compound.
Summary for rifampin
US Patents: | 0 |
Tradenames: | 3 |
Applicants: | 11 |
NDAs: | 15 |
Drug Master File Entries: | 9 |
Finished Product Suppliers / Packagers: | 15 |
Raw Ingredient (Bulk) Api Vendors: | 47 |
Clinical Trials: | 307 |
Patent Applications: | 7,039 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price trends for rifampin |
What excipients (inactive ingredients) are in rifampin? | rifampin excipients list |
DailyMed Link: | rifampin at DailyMed |
Recent Clinical Trials for rifampin
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Guangdong Raynovent Biotech Co., Ltd | Phase 1 |
Hôpital Necker-Enfants Malades | Phase 3 |
Institut Pasteur | Phase 3 |
Pharmacology for rifampin
Drug Class | Rifamycin Antibacterial |
Medical Subject Heading (MeSH) Categories for rifampin
US Patents and Regulatory Information for rifampin
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresenius Kabi Usa | RIFAMPIN | rifampin | INJECTABLE;INJECTION | 091181-001 | Aug 21, 2014 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Epic Pharma Llc | RIFAMPIN | rifampin | CAPSULE;ORAL | 064150-002 | Jan 2, 1998 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sanofi Aventis Us | RIFADIN | rifampin | CAPSULE;ORAL | 050420-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Hikma Pharms | RIFAMPIN | rifampin | INJECTABLE;INJECTION | 205039-001 | Mar 3, 2016 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Lupin Pharms | RIFAMPIN | rifampin | CAPSULE;ORAL | 090034-002 | Aug 21, 2013 | AB | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Chartwell Molecular | RIFAMPIN | rifampin | CAPSULE;ORAL | 065390-001 | Mar 28, 2008 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.